ZYME (Zymeworks Inc.) Stock Financials & Earnings | Market Cap Arena

ZYME (Zymeworks Inc.) Stock Financials & Earnings | Market Cap Arena

ZYMEZymeworks Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Revenue (TTM)$106M

Net Income (TTM)-$81M

EPS (TTM)-$1.08

Free Cash Flow (TTM)-$18.9B

Gross Margin98.4%

Op. Margin-87.3%

Net Margin-76.6%

FCF Margin-17875.7%

P/S Ratio (TTM)18.9x

P/E Ratio (TTM)—

YoY Rev Growth+38.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$36M	-$10M	-$27M
Q2 23	$7M	-$32M	-$54M
Q3 23	$17M	$17M	-$33M
Q4 23	$17M	$17M	-$23M
Q1 24	$10M	$10M	-$38M
Q2 24	$19M	$19M	-$43M
Q3 24	$16M	$16M	-$34M
Q4 24	$31M	$31M	-$22M
Q1 25	$27M	$27M	-$26M
Q2 25	$49M	$49M	-$674K
Q3 25	$28M	$28M	-$22M
Q4 25	$3M	$824K	-$44M

Valuation

Quarter	P/S	P/E
Q1 23	4.5x	11.6x
Q2 23	4.5x	10.8x
Q3 23	4.3x	9.8x
Q4 23	26.4x	—
Q1 24	39.8x	—
Q2 24	32.0x	—
Q3 24	32.3x	—
Q4 24	26.3x	—
Q1 25	21.5x	—
Q2 25	16.3x	—
Q3 25	14.9x	—
Q4 25	18.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$83M	-$84M
Q2 23	-$6M	-$7M
Q3 23	-$43M	-$44M
Q4 23	$14M	$12M
Q1 24	-$38M	-$38M
Q2 24	-$25M	-$26M
Q3 24	-$6M	-$7M
Q4 24	-$42M	-$42M
Q1 25	-$3M	-$4M
Q2 25	$12M	$11M
Q3 25	-$31M	-$32M
Q4 25	-$10M	-$18.9B

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$386K
Q2 23	$802K
Q3 23	$1M
Q4 23	$2M
Q1 24	$654K
Q2 24	$1M
Q3 24	$1M
Q4 24	$314K
Q1 25	$338K
Q2 25	$884K
Q3 25	$410K
Q4 25	$1M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+1756.9%	-15.7%
Q2 23	+28.7%	-14.2%
Q3 23	+527.4%	-6.1%
Q4 23	-95.8%	-51.4%
Q1 24	-71.8%	-23.9%
Q2 24	+174.8%	+1.7%
Q3 24	-3.1%	+0.9%
Q4 24	+83.3%	+32.0%
Q1 25	+170.3%	+10.2%
Q2 25	+153.2%	-20.5%
Q3 25	+72.6%	-1.0%
Q4 25	-91.9%	-12.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$2M	6.5%
Q2 23	$367K	5.2%
Q3 23	$2M	12.4%
Q4 23	$3M	19.9%
Q1 24	$4M	35.4%
Q2 24	$5M	23.7%
Q3 24	$5M	29.1%
Q4 24	$5M	16.2%
Q1 25	$6M	23.6%
Q2 25	$6M	12.0%
Q3 25	$7M	25.0%
Q4 25	-$3.4B	-135615.4%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$46M	$17M
Q2 23	$39M	$22M
Q3 23	$33M	$17M
Q4 23	$26M	$15M
Q1 24	$32M	$1M
Q2 24	$29M	$16M
Q3 24	$36M	$14M
Q4 24	$37M	$16M
Q1 25	$36M	$17M
Q2 25	$34M	$15M
Q3 25	$36M	$14M
Q4 25	$31M	$14M

Revenue Segments

Quarter	Deferred Revenue	Milestone Revenue	Option Exercise Fee	Research Support Payments And Other Service	Royalty
Q2 25	$18M	$20M	$8M	$475K	$550K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$182M	$159M	$341M
Q2 23	$142M	$198M	$340M
Q3 23	$94M	$201M	$295M
Q4 23	$158M	$217M	$374M
Q1 24	$115M	$230M	$345M
Q2 24	$71M	$259M	$330M
Q3 24	$122M	$175M	$297M
Q4 24	$66M	$160M	$226M
Q1 25	$76M	$189M	$265M
Q2 25	$98M	$183M	$281M
Q3 25	$65M	$187M	$252M
Q4 25	$41.2B	$188M	$41.3B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	67M	+0.3%
Q2 23	67M	+0.8%
Q3 23	71M	+4.9%
Q4 23	71M	+0.4%
Q1 24	76M	+7.6%
Q2 24	76M	+0.2%
Q3 24	76M	-0.3%
Q4 24	76M	-0.4%
Q1 25	75M	-0.9%
Q2 25	77M	+2.9%
Q3 25	76M	-2.1%
Q4 25	75M	-0.6%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	—	—
FY 16	—	—
FY 17	—	—
FY 18	—	—
FY 19	—	—
FY 20	—	—
FY 21	—	—
FY 22	$1M	294
FY 23	$274K	277
FY 24	$267K	286
FY 25	$530	200K